Prevalence and risk factors of MAFLD and its metabolic comorbidities in community-based adults in China : A cross-sectional study
Copyright © 2024 Research Trust of DiabetesIndia (DiabetesIndia) and National Diabetes Obesity and Cholesterol Foundation (N-DOC). Published by Elsevier Ltd. All rights reserved..
AIMS: There is a growing interest in the co-management of metabolic dysfunction-associated fatty liver disease (MAFLD) and its metabolic comorbidities. However, there is insufficient epidemiological data regarding MAFLD and its metabolic comorbidities in China. This study aims to investigate the prevalence and risk factors of MAFLD and its metabolic comorbidities.
METHODS: 9171 participants were recruited in this cross-sectional study, utilizing a multistage, stratified sampling method. All participants underwent a comprehensive assessment. The diagnosis of MAFLD was based on vibration-controlled transient elastography (VCTE). The prevalence of MAFLD and its metabolic comorbidities was calculated. Binary and ordinary logistic regressions were conducted.
RESULTS: The overall weighted prevalence of MAFLD was 21.18%. Of the 2081 adults with MAFLD, 1866 (89.67%) had more than one metabolic comorbidity, and only 215 (10.33%) did not have comorbidity. Among the population with MAFLD, the prevalence of dyslipidemia, hypertension, hyperuricemia, and diabetes was 67.47%, 43.73%, 39.10%, and 33.88%, respectively. Advanced age, male gender, overweight/obesity, excessive alcohol consumption, and elevated HOMA-IR levels were positively correlated with the number of MAFLD-related metabolic comorbidities.
CONCLUSIONS: A significant proportion of individuals diagnosed with MAFLD presented with metabolic comorbidities. Therefore, engaging in the co-management of MAFLD and its metabolic comorbidities is imperative.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Diabetes & metabolic syndrome - 18(2024), 3 vom: 07. März, Seite 102973 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
He, Yajun [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Co-management |
|---|
| Anmerkungen: |
Date Revised 17.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.dsx.2024.102973 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369833368 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369833368 | ||
| 003 | DE-627 | ||
| 005 | 20240318235037.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240318s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.dsx.2024.102973 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1335.xml |
| 035 | |a (DE-627)NLM369833368 | ||
| 035 | |a (NLM)38493648 | ||
| 035 | |a (PII)S1871-4021(24)00034-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a He, Yajun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prevalence and risk factors of MAFLD and its metabolic comorbidities in community-based adults in China |b A cross-sectional study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 17.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2024 Research Trust of DiabetesIndia (DiabetesIndia) and National Diabetes Obesity and Cholesterol Foundation (N-DOC). Published by Elsevier Ltd. All rights reserved. | ||
| 520 | |a AIMS: There is a growing interest in the co-management of metabolic dysfunction-associated fatty liver disease (MAFLD) and its metabolic comorbidities. However, there is insufficient epidemiological data regarding MAFLD and its metabolic comorbidities in China. This study aims to investigate the prevalence and risk factors of MAFLD and its metabolic comorbidities | ||
| 520 | |a METHODS: 9171 participants were recruited in this cross-sectional study, utilizing a multistage, stratified sampling method. All participants underwent a comprehensive assessment. The diagnosis of MAFLD was based on vibration-controlled transient elastography (VCTE). The prevalence of MAFLD and its metabolic comorbidities was calculated. Binary and ordinary logistic regressions were conducted | ||
| 520 | |a RESULTS: The overall weighted prevalence of MAFLD was 21.18%. Of the 2081 adults with MAFLD, 1866 (89.67%) had more than one metabolic comorbidity, and only 215 (10.33%) did not have comorbidity. Among the population with MAFLD, the prevalence of dyslipidemia, hypertension, hyperuricemia, and diabetes was 67.47%, 43.73%, 39.10%, and 33.88%, respectively. Advanced age, male gender, overweight/obesity, excessive alcohol consumption, and elevated HOMA-IR levels were positively correlated with the number of MAFLD-related metabolic comorbidities | ||
| 520 | |a CONCLUSIONS: A significant proportion of individuals diagnosed with MAFLD presented with metabolic comorbidities. Therefore, engaging in the co-management of MAFLD and its metabolic comorbidities is imperative | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Co-management | |
| 650 | 4 | |a Metabolic comorbidity | |
| 650 | 4 | |a Metabolic dysfunction-associated fatty liver disease | |
| 650 | 4 | |a Prevalence | |
| 650 | 4 | |a Risk factors | |
| 700 | 1 | |a Yao, Nanfang |e verfasserin |4 aut | |
| 700 | 1 | |a Tian, Feng |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Lingling |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Xu |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Xingying |e verfasserin |4 aut | |
| 700 | 1 | |a Duan, Hualin |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Yuqi |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Genfeng |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Cheng |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Dongmei |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Qintao |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Lan |e verfasserin |4 aut | |
| 700 | 1 | |a Wan, Heng |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Jie |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Diabetes & metabolic syndrome |d 2007 |g 18(2024), 3 vom: 07. März, Seite 102973 |w (DE-627)NLM189445564 |x 1878-0334 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2024 |g number:3 |g day:07 |g month:03 |g pages:102973 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.dsx.2024.102973 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2024 |e 3 |b 07 |c 03 |h 102973 | ||